PhaseBio Pharmaceuticals Revenue and Competitors

Location

$324.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • PhaseBio Pharmaceuticals's estimated annual revenue is currently $2M per year.(i)
  • PhaseBio Pharmaceuticals's estimated revenue per employee is $77,500
  • PhaseBio Pharmaceuticals's total funding is $324.3M.

Employee Data

  • PhaseBio Pharmaceuticals has 26 Employees.(i)
  • PhaseBio Pharmaceuticals grew their employee count by -63% last year.

PhaseBio Pharmaceuticals's People

NameTitleEmail/Phone
1
SVP, Technical OperationsReveal Email/Phone
2
VP, Research & Scientific AffairsReveal Email/Phone
3
Head Clinical ResearchReveal Email/Phone
4
DIRECTOR, MARKETINGReveal Email/Phone
5
Chief Medical OfficerReveal Email/Phone
6
Director, Trial Master FileReveal Email/Phone
7
Chief Commercial OfficerReveal Email/Phone
8
Senior Manager, Analytical/QCReveal Email/Phone
9
Sr. Manager, CMC Quality AssuranceReveal Email/Phone
10
Manager, Clinical Supply ChainReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is PhaseBio Pharmaceuticals?

PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our elastin-like polypeptide technology, which also serves as the engine for our preclinical pipeline. Our proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which may lead to less-frequent dosing and better patient compliance. PB1046 is a vasoactive intestinal peptide (VIP) receptor agonist that leverages our ELP technology for once-weekly dosing. PB1046 is being evaluated in clinical studies in pulmonary arterial hypertension (PAH) and in preclinical studies for the treatment of cardiomyopathy associated with dystrophinopathies. PhaseBio recently concluded a Phase 2a trial of PB1046 in patients with heart failure with reduced ejection fraction. We are also evaluating our development candidate PB2452, a reversal agent for the antiplatelet therapy ticagrelor, in clinical trials. PB2452 was exclusively licensed from MedImmune, the global biologics research and development arm of AstraZeneca, for global development and commercialization by PhaseBio. PhaseBio continues to explore opportunities to apply our ELP biopolymer technology to compounds that may benefit from its unique properties. We are privately owned, with headquarters and research laboratories in Malvern, PA.

keywords:N/A

$324.3M

Total Funding

26

Number of Employees

$2M

Revenue (est)

-63%

Employee Growth %

N/A

Valuation

N/A

Accelerator

PhaseBio Pharmaceuticals News

2022-04-20 - Is PhaseBio Pharmaceuticals Inc (PHAS) Stock a Bad Value?

PhaseBio Pharmaceuticals Inc (PHAS) stock is down -61.44% over the last 12 months, and the average rating from Wall Street analysts is a...

2022-04-06 - PhaseBio Announces Positive Results from Phase 2b Trial for ...

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on...

2022-03-22 - PhaseBio Pharmaceuticals Reports Fourth Quarter and Full ...

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies...

2021-03-15 - PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 15, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth-q ...

2021-03-11 - PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 11, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.6M28-32%N/A
#2
$5.7M28-10%N/A
#3
$8.5M3011%N/A
#4
$3.5M30-14%N/A
#5
$5.5M31-3%N/A